论文部分内容阅读
目的研究头孢匹罗治疗社区获得性肺炎(CAP)的临床疗效和安全性。方法 60例CAP患者随机分为试验组和对照组,试验组给予头孢匹罗治疗,对照组给予头孢地嗪治疗,疗程7～14d。结果试验组、对照组临床有效率分别为93.3%和70%,细菌清除率分别为92%和65.2%,两组治疗不良反应均轻微,安全性好。结论头孢匹罗治疗社区获得性肺炎疗效显著,细菌清除率高,优于头孢地嗪。
Objective To study the clinical efficacy and safety of cefpirome in the treatment of community-acquired pneumonia (CAP). Methods Sixty patients with CAP were randomly divided into experimental group and control group. The experimental group was treated with cefpirome and the control group with cefodizime. The course of treatment was 7 to 14 days. Results The clinical efficacies of the experimental group and the control group were 93.3% and 70%, respectively, and the bacterial clearance rate was 92% and 65.2% respectively. Both groups had mild adverse reactions and good safety. Conclusion Cefpilomex is effective in treating community-acquired pneumonia with high bacterial clearance and superiority to cefodizime.